I'm long this stock and believe in the company. I am not however very confident that the NSLC data will prove to be positive. I think the company will cut vintafolide and move onto Tubulysin. I do hope for good news since I'm horribly in the red, but I'm not holding my breath. Could see the mid 5's before something significant comes from Tubulysin.
Appreciate the input. I wasa #$%$ and held all the way through this positive news. Never thought the bottom would drop out on the phase III since it seemed to be doing well.
I'm not exactly feeling confident in the lung cancer trial. Tubulysin as you said seems promising. I think the technology is good and works, but they have an issue with the medicine part. This is a rough place to be.